Sign in

Bryan Dickinson

@chembiobryan.bsky.social
1.9K followers 352 following 179 posts

chemical/synthetic biologist, trying to find better ways to make molecules that do important stuff, dad, @uchicago professor of chemistry www.dickinsonlab.uchicago.edu

PostsRepliesMedia
Reposted by Bryan Dickinson
Nicolas Hénin @nicolashenin.net · 17/09/2026
Nice campaign by the Norwegian Consumer Council about the declining lifespan of products. Enjoy!
181140946478
Reposted by Bryan Dickinson
EMBL Events @events.embl.org · 14/09/2026
And that's a wrap on the EMBO Workshop 'Chemical biology 2026'! #EMBOChemBio A huge thank you to everyone who joined us - from exciting science to lively discussions over coffee, it was a fantastic few days of exchanging ideas, making connections, and exploring the latest in chemical biology ⚗️🧪
1156
Reposted by Bryan Dickinson
Maja Köhn @mkoehn.bsky.social · 09/09/2026
Finished the first day of #EMBOChemBio with an inspiring keynote by Bill De Grado on design of proteins with various functions. Now off to an exciting second day! Started by Hermen Overkleeft on the complexity of glycosidases and their amazing work to tackle them with activity based probes #ChemBio
153
Reposted by Bryan Dickinson
Maja Köhn @mkoehn.bsky.social · 09/09/2026
From detection of new PTMs (Chu Wang), diverse approaches to target protein aggregation (Mi Hee Lim) to new photocage designs (Peter Kele) and target ID of new electrophiles (Yimon Aye): #EMBOChemBio offers to learn from different areas and amazing methods to inspire own research! #ChemBio #ChemSky
043
Reposted by Bryan Dickinson
Maja Köhn @mkoehn.bsky.social · 08/09/2026
Great talk today by Ben Lehner on how to find allosteric sites in proteins by mutational mapping of proteins for effects on binding and stability. Huge amounts of data, important applications. Great start of the conference! #EMBOChemBio
142
Reposted by Bryan Dickinson
EMBL Events @events.embl.org · 09/09/2026
Day 2 of the EMBO Workshop 'Chemical biology 2026' is in full swing ⚗️🤓 🔵 Session 2: Chemical technologies to probe biology 🎤 'Cartographing local proteomes’ actionability' presented by Yimon Aye (University of Oxford, UK) + lots of coffee! #EMBOChemBio @embl.org @embo.org
0103
Reposted by Bryan Dickinson
EMBL Events @events.embl.org · 10/09/2026
Poster session: where “I’ll just have a quick look” somehow turns into a 20-minute scientific deep dive 😄🧪 Yesterday’s poster session at 'Chemical biology' had all the right ingredients: a little chemistry, a little biology, and a lot of interaction ⚗️💬 #EMBOChemBio @embl.org @embo.org
0154
Reposted by Bryan Dickinson
EMBL Events @events.embl.org · 08/09/2026
Welcome to Day 1 of 'Chemical biology 2026'! Looking forward to the next 4 days packed with science and new connections ⚗️🤩 ➡️ Opening remarks by one of our scientific organisers Bryan Dickinson (University of Chicago, USA) #EMBOChemBio @embl.org @embo.org @chembiobryan.bsky.social
1166
Bryan Dickinson @chembiobryan.bsky.social · 08/09/2026
Check out our recent News and Views of fantastic work from Peng Zou’s group Directed evolution + proximity chemistry = key to my heart www.nature.com/articles/s41...
nature.com
Evolving faster proximity chemistry - Nature Chemical Biology
By evolving a flavoprotein in mammalian cells, a super-fast, genetically encoded photocatalyst called Lantern was developed, allowing the mapping of dynamic RNA and protein organization at high spatio...
064
Bryan Dickinson @chembiobryan.bsky.social · 11/08/2026
Big faculty search in chemical biology, campus-wide, at University of Chicago! Come be my colleague! This is a special place! apply.interfolio.com/190752
apply.interfolio.com
Apply - Interfolio {{$ctrl.$state.data.pageTitle}} - Apply - Interfolio
11911
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
14/ This area in the group is cookin! Lots more to come!!
010
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
13/ This work adds to our repertoire of high-quality selection systems we built, including our PANCS_spec-binders tech: www.pnas.org/doi/10.1073/... and our work on rapid biological tool development: pubs.acs.org/doi/10.1021/...
pnas.org
PANCS-spec-Binders: A system for rapidly discovering isoform- or epitope-specific binders | PNAS
Proteins that bind to a target protein of interest, termed “binders”, are essential components of biological research reagents and therapeutics. Ta...
110
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
12/ They work in cells. Delivered pen-Raf variants shut down pERK driven by KRAS G12D. SGAD displaces Max from endogenous Myc by co-IP. TWAA turns on p53 transcription. Both affibodies sit near 0.5 µM — the kind of binder an affinity-first selection would never find.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
11/ Discovery mode: a ~10^8 affibody library against Mdm2–p53 and Myc–Max returned de novo inhibitors of both. The Myc–Max hit is the head-to-head — same proteins, same library design, and binder selections had given us only non-inhibitors.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
10/ Near-complete coverage lets us test a live argument in the field. Singles predicting higher-order fitness: r = 0.54. Add doubles (median): r = 0.61. Take the best double-based prediction: r = 0.90. The information is in the doubles — you just can't tell which pairing dominates.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
9/ The landscape is rugged. Hierarchical clustering of the top 1000 variants yields 118 distinct solutions. Positions 85 and 88 co-converge 67% of the time; position 81 floats nearly free. You can explore the landscape yourself with our web app: bryandickinson-create.github.io/dms-fitness-...
bryandickinson-create.github.io
DMS Fitness Explorer: Raf
Interactive explorer for deep mutational scanning data on the Ras–Raf interface
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
8/ Then we pushed it as a measurement tool. Deep mutational scan (DMS) of pen-Raf: four positions fully randomized (NNK), 160,000 protein variants. We recovered 99% of full-length protein variants - perhaps one of the largest DMS experiments ever performed.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
7/ Mock selections: 10 inhibitor phage spiked into 10^10 empty phage. After 3–8 overnight passages the inhibitor takes over — at least 10^14-fold relative enrichment, in days. Works for several important human therapeutic targets: KRas–Raf, Mdm2–p53, and Myc–Max.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
6 / See if you can follow the logic! This may be the most complex selection we ever built! All the pressure lands on one interaction.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
5/ On infection RNAP-N is recruited to both targets. The control PPI drives gIII (phage need it). The target PPI drives a dominant-negative gIII (poison). Disrupt the target PPI → poison off → phage replicates. Disrupt anything else → no gIII → dead.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
4/ PANCS-Inhibitors makes phage replication depend on PPI disruption - not just binding. Phage carry RNAP-N fused to a zipper (ZP1) plus a candidate inhibitor. The E. coli host holds two trimolecular complexes: your target PPI, and a control PPI (eg ZA–ZB).
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
3/ How hard is it to discovery inhibitors? We took binders from our own prior campaigns and tested them for inhibition. Mdm2 binders: all inhibited. KRas binders: zero. Myc/Max binders: zero. Raf binders: 3/5. Binding alone may a poor proxy for the function you want. www.nature.com/articles/s41...
nature.com
PANCS-Binders: a rapid, high-throughput binder discovery platform - Nature Methods
Phage-assisted noncontinuous selection of protein binders (PANCS-Binders) allows multiple high-diversity protein libraries to each be screened against a panel of dozens of targets for high-throughput ...
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
2/ The problem: There are 10s of thousands of human PPI targets. Binder discovery is not becoming more routine, but binders interact with hot-spots, which may or may not target a specific interface, and allosteric sites are hard to predict a priori.
100
Bryan Dickinson @chembiobryan.bsky.social · 06/08/2026
1/ Binder ≠ inhibitor. Most PPI inhibitor campaigns find a binder first, then hope it blocks the target protein-protein interaction. We built a system that skips the hoping and selects directly for disruption of a pre-formed PPI. Meet PANCS-Inhibitors. 🧵 www.biorxiv.org/content/10.6...
biorxiv.org
PANCS-Inhibitors: A rapid method to directly select for protein-protein interaction inhibitors
Aberrant protein-protein interactions (PPIs) drive myriad diseases. Inhibiting these PPIs often relies on discovering molecules that bind to one of the proteins and hoping that this binding inhibits t...
12211
Reposted by Bryan Dickinson
AACR Journals @aacrjournals.bsky.social · 08/07/2026
Welcome Molecular Cancer Therapeutics Senior Editor Bryan Dickinson, PhD, who brings expertise in chemical biology, protein engineering, and RNA-targeting therapeutics. Learn more about the journal: buff.ly/SvrkEMr @chembiobryan.bsky.social
061
Bryan Dickinson @chembiobryan.bsky.social · 07/07/2026
I'm becoming this cranky old man....
010
Bryan Dickinson @chembiobryan.bsky.social · 01/07/2026
I learned a new word today! "Polyspecificity" Our binders aren't non-specific. They are POLYspecific! I am very POLYimpressed by this research.nvidia.com/labs/genair/...
research.nvidia.com
Proteina-Complexa
Proteina-Complexa combines joint sequence-structure generation in a continuous latent space with inference-time search for de novo protein binder design. In a massive-scale experimental benchmark — o...
130
Bryan Dickinson @chembiobryan.bsky.social · 09/06/2026
Nice article about Josh and Matt and their work together on this paper. Uchicago undergrads are very special! chemistry.uchicago.edu/news/new-uch...
chemistry.uchicago.edu
New UChicago Platform Rapidly Generates Custom Protein Binders to Target Disease
How an innovative UChicago laboratory built a fast-moving platform to target "undruggable" cancer proteins and train the next generation of scientific leaders
070
Bryan Dickinson @chembiobryan.bsky.social · 02/06/2026
This work is now out at @pnas.org In drug discovery it’s often said selectivity is key - and here is a solution! Our PANCS platforms continue to expand! www.pnas.org/doi/10.1073/...
pnas.org
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
0102
Reposted by Bryan Dickinson
Carolyn Bertozzi @carolynbertozzi.bskyverified.social · 28/05/2026
The leadership and clarity of @MIT President Sally Kornbluth www.bostonglobe.com/2026/05/26/o...
bostonglobe.com
America built the world’s greatest research engine. Now it’s shrinking. - The Boston Globe
At public and private universities across the country, high-impact science is being damaged and derailed.
412855
Bryan Dickinson @chembiobryan.bsky.social · 26/05/2026
Wow - what a lineup for the SMART Symposium on the Expanding Genetic Code and Beyond & GCE Workshop in Shenzhen!!! If you are in China definitely this is the conference to attend this Fall! symposia.smart.org.cn/sym/event/Fu...
symposia.smart.org.cn
Symposia
100
Reposted by Bryan Dickinson
Stephanie M. Lee @stephaniemlee.bsky.social · 21/05/2026
NEW: They Got the Best NIH Scores of Their Careers. A Year Later, They Still Don’t Have Funding. As the NIH bankrolls new research at a significantly slower-than-usual pace, I talked to scientists left in the lurch about the toll on their research and careers: www.chronicle.com/article/they...
chronicle.com
They Got the Best NIH Scores of Their Careers. A Year Later, They Still Don’t Have Funding.
The NIH’s spending on new medical research is significantly slower than in previous years, leaving confused scientists in the lurch.
014081
Bryan Dickinson @chembiobryan.bsky.social · 22/05/2026
Our more recent paper is hot off the press in @jacs.acspublications.org Great team effort and a preview of what the future looks like for our group.... pubs.acs.org/doi/full/10....
pubs.acs.org
A Rapid Binder Discovery Workflow for Engineering Mini-Protein Degraders
Developing molecules that selectively bind targets of interest remains a critical bottleneck in biological research and biotechnology. Here, we present a workflow that leverages the Phage-Assisted Non-Continuous Selection for Binders (PANCS-Binders) technology for rapid de novo binder discovery. To directly assess the speed and utility of the approach, we pursued three cancer-related targets: NSD3, NMNAT2, and CSF1R. Within 26 days, the PANCS-Binders workflow yielded sequence- and function-verified binders for all three targets with nano-to-micromolar affinities. By incorporating an NSD3 binder into an engineered E3 ligase, RNF8, we developed an NSD3 degrader that potently depleted endogenous NSD3 and inhibited colorectal cancer cell proliferation. We then applied this degrader to reveal previously unknown NSD3 dependencies in ovarian cancer cell lines, uncovering new therapeutic vulnerabilities. Together, our work establishes a robust workflow for accelerated binder discovery and demonstrates how binders can expedite chemical biology discovery and biotechnology development.
0205
Bryan Dickinson @chembiobryan.bsky.social · 19/05/2026
See our thoughts and overview on the field of binder discovery! Also it has a bit of an update on some of our own work pushing to new directions www.sciencedirect.com/science/arti...
sciencedirect.com
Toward universal binder discovery: Advances in display, computational design and in vivo platforms
Protein binders are fundamental tools in chemical biology, key components of biotechnologies, and the foundation of biologics-based medicines. However…
052
Bryan Dickinson @chembiobryan.bsky.social · 19/05/2026
See our recent review on proximity chemistry to study RNA biology. If you are interested in getting into the field, this is an easy way to get caught up on the chemistry and technology: www.sciencedirect.com/science/arti...
sciencedirect.com
Proximity chemistries to study RNA biology at the subcellular scale
RNAs preferentially localize across virtually every subcellular compartment, from membrane-bound organelles, membrane-less condensates and even the ce…
0216
Reposted by Bryan Dickinson
Lemke Lab @lemkelab.bsky.social · 21/05/2025
Save the date! 🧪The EMBO Workshop on Chemical Biology returns to EMBL Heidelberg on 8–11 Sep 2026. Co-organisers: Bryan Dickinson (UChicago), Maja Köhn (Bonn), Edward Lemke (IMB), Xiao Wang (MIT). #ChemicalBiology #EMBOChemBio #EMBO #EMBL #SaveTheDate #Biotech #Science www.embl.org/about/info/c...
embl.org
Chemical biology
093
Reposted by Bryan Dickinson
Anna Wuttig @annawuttig.bsky.social · 31/03/2026
My lab’s next paper is out in JACS! Congrats to Taemin and Ching who discovered that Brønsted acids unlock mild interfacial catalytic halogen atom transfer at Ag electrodes! pubs.acs.org/doi/10.1021/...
083
Bryan Dickinson @chembiobryan.bsky.social · 30/03/2026
Grateful to iDefine for supporting a new project aimed ultimately at helping these patients. www.idefine.org
idefine.org
Kleefstra Syndrome
Building abrighter future. IDefine is committed to identifying life-changing treatments & cures for those with Kleefstra syndrome (KS), a neurodevelopmental disorder caused by a loss of function in on...
092
Bryan Dickinson @chembiobryan.bsky.social · 06/03/2026
Check out our new review on binder discovery! In a fast-moving world, here are some thoughts we have in the moment. Congrats @jzy2799.bsky.social and Eddy!! www.sciencedirect.com/science/arti...
sciencedirect.com
Toward universal binder discovery: Advances in display, computational design and in vivo platforms
Protein binders are fundamental tools in chemical biology, key components of biotechnologies, and the foundation of biologics-based medicines. However…
0196
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
Huge congrats to rockstar grad student Riley - who led all aspects of this work, from design, to engineering, to deployment and in vivo testing. This is a tour de force in preclinical development.
010
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
This work validates translational activation as a therapeutic strategy for haploinsufficiency. With ~3000 dosage-sensitive genes and limited tools to address underexpression, CIRTS-4GT3 opens new possibilities for precision gene expression control.
130
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
This is the first demonstration that targeted translational activation can rescue a haploinsufficiency phenotype in vivo. The approach offers unique advantages: no permanent DNA changes, mRNA-level specificity, and protein increases matched to cellular context.
120
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
Beyond SCN1a: CIRTS-4GT3 also increased protein expression from CHD2 (epilepsy/developmental delay) and ARID1B (intellectual disability/autism) by 50-100%. The platform is programmable—just change the guide RNA to target new transcripts.
120
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
The results were striking: Female SCN1a+/− mice showed 50% mortality by P50. With CIRTS-4GT3 treatment? Only 13% mortality. We also saw significantly higher seizure thresholds in treated mice—key functional improvements.
120
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
We tested this in Dravet syndrome—a severe epilepsy caused by SCN1a haploinsufficiency affecting 1:15,000 people. AAV9 delivery of CIRTS-4GT3 targeting SCN1a to neonatal mice increased NaV1.1 protein ~25% in cortex and hippocampus.
120
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
Key advantages of CIRTS-4GT3: (1) Flexible gRNA design targeting 5' or 3' UTRs, (2) fits in single AAV vectors, (3) made entirely from human proteins (reduced immunogenicity), (4) protein boost scales with endogenous mRNA levels—no overexpression toxicity.
120
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
We screened 11 translational effector domains and optimized eIF4GI truncations to create CIRTS-4GT3—a compact 601 amino acid activator that doubles target protein expression. It works by recruiting eIF3 and the translation machinery to guide RNA-targeted mRNAs.
110
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
Our approach: Use CIRTS (CRISPR-inspired RNA-targeting system) to programmably increase translation from endogenous mRNAs. Unlike gene therapy, this boosts protein only in cells that already express the target mRNA—built-in cell-type specificity. www.cell.com/cell/fulltex...
cell.com
Programmable RNA-Guided RNA Effector Proteins Built from Human Parts
Engineered modular RNA-guided RNA-targeting effectors synthesized entirely from human protein parts provide a set of new tools that might overcome the size and immunogenicity limitations of CRISPR-Cas...
110
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
The challenge: ~3000 "dosage-sensitive" genes cause disease through haploinsufficiency (loss of one copy = ~50% protein). Brain genes are especially sensitive. We have great tools to knock genes DOWN, but few to boost them UP—especially in neurons.
110
Bryan Dickinson @chembiobryan.bsky.social · 16/02/2026
Excited to share our new work in @narjournal.bsky.social ! We engineered a human-based translational activator that rescued phenotypes in a Dravet syndrome mouse model by boosting protein expression from haploinsufficient genes. A thread on targeting translation 🧵 academic.oup.com/nar/article/...
academic.oup.com
Engineering a human-based translational activator for targeted protein expression restoration
Abstract. Therapeutic modalities to programmably increase protein production are in critical need to address diseases caused by deficient gene expression v
1218